Is a Cancer-Specific Fusion Gene Recurrent in High-Grade Serous Ovarian Carcinoma

English version České info

High-grade serous carcinoma (HG-SC) is the most common subtype of ovarian cancer observed in women. This subtype of ovarian cancer is typically detected at advanced stages due to lack of effective early screening tools. Recurrent cancer-specific gene fusions resulting from chromosomal translocations have the potential to serve as effective screening tools as well as therapeutic targets. Here we identified CDKN2D-WDFY2 as a cancer-specific fusion gene present in 20% of HG-SC tumors, by far the most frequent gene recombinant event found in this highly heterogeneous disease. We also presented evidence that the expression of this fusion may affect the PI3K/AKT pathway that is important for cancer progression. Thus CDKN2D-WDFY2 could very well represent a major cellular lineage important for detecting and classifying heterogeneous ovarian carcinomas, and could provide insight into the underlying mechanism of this deadly disease. This is critical, given that ovarian cancer kills 140,200 women worldwide each year, and few ovarian cancer-specific molecular alterations are currently available for targeting and screening.

Vyšlo v časopise: Is a Cancer-Specific Fusion Gene Recurrent in High-Grade Serous Ovarian Carcinoma. PLoS Genet 10(3): e32767. doi:10.1371/journal.pgen.1004216
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1004216

Souhrn

Zdroje

1. JemalA, BrayF, CenterMM, FerlayJ, WardE, et al. (2011) Global cancer statistics. CA Cancer J Clin 61: 69–90.

2. BellDBA, BirrerM, ChienJ, CramerDW, et al. (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609–615.

3. MitelmanF, JohanssonB, MertensF (2007) The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 7: 233–245.

4. PernerS, DemichelisF, BeroukhimR, SchmidtFH, MosqueraJM, et al. (2006) TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res 66: 8337–8341.

5. TomlinsSA, RhodesDR, PernerS, DhanasekaranSM, MehraR, et al. (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644–648.

6. McPhersonA, HormozdiariF, ZayedA, GiulianyR, HaG, et al. (2011) deFuse: an algorithm for gene fusion discovery in tumor RNA-Seq data. PLoS Comput Biol 7: e1001138.

7. SalzmanJ, MarinelliRJ, WangPL, GreenAE, NielsenJS, et al. (2011) ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma. PLoS Biol 9: e1001156.

8. LeeY, MironA, DrapkinR, NucciMR, MedeirosF, et al. (2007) A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211: 26–35.

9. PothuriB, LeitaoMM, LevineDA, VialeA, OlshenAB, et al. (2010) Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS One 5: e10358.

10. KentWJ (2002) BLAT–the BLAST-like alignment tool. Genome Res 12: 656–664.

11. KannanK, WangL, WangJ, IttmannMM, LiW, et al. (2011) Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. Proc Natl Acad Sci U S A 108: 9172–9177.

12. LieberMR (2010) The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 79: 181–211.

13. WeierC, HaffnerMC, MosbrugerT, EsopiDM, HicksJ, et al. (2013) Nucleotide resolution analysis of TMPRSS2 and ERG rearrangements in prostate cancer. J Pathol 230: 174–183.

14. FritziusT, BurkardG, HaasE, HeinrichJ, SchwenekerM, et al. (2006) A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda. Biochem J 399: 9–20.

15. FritziusT, MoellingK (2008) Akt- and Foxo1-interacting WD-repeat-FYVE protein promotes adipogenesis. EMBO J 27: 1399–1410.

16. TibesR, QiuY, LuY, HennessyB, AndreeffM, et al. (2006) Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5: 2512–2521.

17. OrtegaS, MalumbresM, BarbacidM (2002) Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602: 73–87.

18. CerutiJM, ScassaME, FloJM, VaroneCL, CanepaET (2005) Induction of p19INK4d in response to ultraviolet light improves DNA repair and confers resistance to apoptosis in neuroblastoma cells. Oncogene 24: 4065–4080.

19. ScassaME, MarazitaMC, CerutiJM, CarcagnoAL, SirkinPF, et al. (2007) Cell cycle inhibitor, p19INK4d, promotes cell survival and decreases chromosomal aberrations after genotoxic insult due to enhanced DNA repair. DNA Repair (Amst) 6: 626–638.

20. ZindyF, van DeursenJ, GrosveldG, SherrCJ, RousselMF (2000) INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol 20: 372–378.

21. HayakawaA, LeonardD, MurphyS, HayesS, SotoM, et al. (2006) The WD40 and FYVE domain containing protein 2 defines a class of early endosomes necessary for endocytosis. Proc Natl Acad Sci U S A 103: 11928–11933.

22. CoarfaC, YuF, MillerCA, ChenZ, HarrisRA, et al. (2010) Pash 3.0: A versatile software package for read mapping and integrative analysis of genomic and epigenomic variation using massively parallel DNA sequencing. BMC Bioinformatics 11: 572.

23. LiH, DurbinR (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754–1760.

24. OryDS, NeugeborenBA, MulliganRC (1996) A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci U S A 93: 11400–11406.

25. NeeleyES, BaggerlyKA, KornblauSM (2012) Surface Adjustment of Reverse Phase Protein Arrays using Positive Control Spots. Cancer Inform 11: 77–86.

26. NeeleyES, KornblauSM, CoombesKR, BaggerlyKA (2009) Variable slope normalization of reverse phase protein arrays. Bioinformatics 25: 1384–1389.